ATE132164T1 - Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors - Google Patents

Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Info

Publication number
ATE132164T1
ATE132164T1 AT88905539T AT88905539T ATE132164T1 AT E132164 T1 ATE132164 T1 AT E132164T1 AT 88905539 T AT88905539 T AT 88905539T AT 88905539 T AT88905539 T AT 88905539T AT E132164 T1 ATE132164 T1 AT E132164T1
Authority
AT
Austria
Prior art keywords
insulin
growth factor
inhibiting
increase
effect
Prior art date
Application number
AT88905539T
Other languages
English (en)
Inventor
David R Clemmons
Walker H Busby Jr
Michael T Brewer
Stephen P Eisenberg
Robert C Thompson
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Application granted granted Critical
Publication of ATE132164T1 publication Critical patent/ATE132164T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polymerisation Methods In General (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT88905539T 1988-04-12 1988-06-03 Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors ATE132164T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18075988A 1988-04-12 1988-04-12

Publications (1)

Publication Number Publication Date
ATE132164T1 true ATE132164T1 (de) 1996-01-15

Family

ID=22661666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905539T ATE132164T1 (de) 1988-04-12 1988-06-03 Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Country Status (7)

Country Link
EP (1) EP0418230B1 (de)
JP (1) JPH03504597A (de)
AT (1) ATE132164T1 (de)
AU (1) AU1955388A (de)
BR (1) BR8901711A (de)
DE (1) DE3854842T2 (de)
WO (1) WO1989009792A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5324820A (en) * 1988-07-15 1994-06-28 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
US6465423B1 (en) 1988-07-15 2002-10-15 Central Sydney Area Health Service Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex
EP0424416B1 (de) * 1988-07-15 1995-07-19 Central Sydney Area Health Service Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein-komplexes
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
WO1992003152A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein (igfbp-4)
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
DE69233155T2 (de) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
ATE243712T1 (de) 1992-11-04 2003-07-15 Chiron Corp Vekürztes insulinähnlichen wachstumsfaktor- bindendes protein mit mitogener aktivität
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
EP0708655A1 (de) * 1993-04-07 1996-05-01 Amgen Boulder Inc. Methoden zur Vewendung des insulinartigenWachstumsfaktor-bindendes Proteins
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60042550D1 (de) 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
EP1670822A2 (de) 2003-10-03 2006-06-21 Genentech, Inc. Igf-bindende proteine
WO2019051474A1 (en) 2017-09-11 2019-03-14 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES
JP7827315B2 (ja) 2020-10-19 2026-03-10 オーク ヒル バイオ リミテッド 新生児における使用に好適な組成物
AU2023210427A1 (en) 2022-01-19 2024-08-22 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4665383A1 (de) 2023-02-14 2025-12-24 Oak Hill Bio Limited Behandlung von heilungsdysregulation in gi-gewebe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
CA1209501A (en) * 1982-09-16 1986-08-12 Nikos Panayotatos Expression vector
AU627423B2 (en) * 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur

Also Published As

Publication number Publication date
EP0418230A1 (de) 1991-03-27
EP0418230A4 (en) 1991-10-23
BR8901711A (pt) 1989-11-21
WO1989009792A1 (en) 1989-10-19
DE3854842T2 (de) 1996-06-13
AU1955388A (en) 1989-11-03
JPH03504597A (ja) 1991-10-09
EP0418230B1 (de) 1995-12-27
DE3854842D1 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
ATE132164T1 (de) Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
DE69433934D1 (de) Verfahren und Zusammensetzungen zur erhöhten Proteinproduktion von rekombinanter DNA
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
DE69922228D1 (de) Verfahren zur reduzierung der mineralisierung von gewebe zum gebrauch bei transplantation
DE69534702D1 (de) Verfahren zur erhöhung der expression von endogenen peptiden tragenden mhc klasse i molekulen
DE59401383D1 (de) Verfahren zur Herstellung von aminosubstituierten Thioethern
ATE250424T1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
DE69327755D1 (de) Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69521539D1 (de) Verfahren zur Herstellung von in organischen Lösungsmitteln löslichen Polytitanosiloxanen
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
MX9203519A (es) Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos.
FI954805A0 (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE69417018D1 (de) Verfahren zur behandlung von teilchenmaterial
DE69720738D1 (de) Zusammensetzung und verfahren zur verhinderung von proteinablagerung auf kontaktlinsen
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69202522D1 (de) Verfahren zur Enthaarung von Tierhäuten.
ATE250132T1 (de) Verfahren zur extraktion von periplasmatischen proteinen aus prokaryotischen mikroorganismen in der anwesenheit von arginin
DE69822526D1 (de) Verfahren zur Konservierung von wassergefüllten Materialien
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
DE69427290D1 (de) Verfahren zur induktion des todes von tumorzellen
DE69409297D1 (de) Verfahren zur Vernetzung von Organosiloxanzusammensetzungen bei Anwesenheit von Vernetzungsinhibitoren
DE69406368D1 (de) Verfahren zur Herstellung von Nitroanilinderivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee